Patent · US Active

Protease stabilized, pegylated insulin analogues and uses thereof

US8987197B2 · kind B2 · utility

0Cited by

3References

10Claims

0Family size

Assignee

Novo Nordisk A/S · DK

Inventors

Peter Madsen · Avenue Madeleine, DK
Thomas Hoeg-Jensen · Klampenborg, DK
Thomas Børglum Kjeldsen · Avenue Madeleine, DK
Tina Møller Tagmose · Rang Taché Est, DK

Key dates

Filing date	Nov 29, 2011
Grant date	Mar 24, 2015
Priority date	—
Expiry date	Nov 29, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/62
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel PEGylated insulin analogs exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogs contain B25H and A14E or A14H. The PEGylation is at B29K.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.